ARIX BIOSCIENCE HOLDINGS LIMITED
Get an alert when ARIX BIOSCIENCE HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-06 (in 5mo)
Last made up 2025-09-22
Watchouts
Cash
£3M
+3,446.5% vs 2023
Net assets
£39M
-11.7% vs 2023
Employees
4
-55.6% vs 2023
Profit before tax
£4M
-58.8% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
While the company has ceased to trade, the Directors do not consider it appropriate to adopt the going concern basis.
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Name history
Renamed 1 time since incorporation
- ARIX BIOSCIENCE HOLDINGS LIMITED 2016-04-15 → present
- PERCEPTIVE BIOSCIENCE HOLDINGS LIMITED 2015-09-23 → 2016-04-15
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £13,000 | £2,000 | |
| Operating profit | £10,536,000 | £4,366,000 | |
| Profit before tax | £10,620,000 | £4,376,000 | |
| Net profit | £10,620,000 | £2,408,000 | |
| Cash | £86,000 | £3,050,000 | |
| Total assets less current liabilities | £44,247,000 | £39,060,000 | |
| Net assets | £44,247,000 | £39,060,000 | |
| Equity | £44,247,000 | £39,060,000 | |
| Average employees | 9 | 4 | |
| Wages | £684,000 | £1,188,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 81046.2% | 218300.0% | |
| Net margin | 81692.3% | 120400.0% | |
| Return on capital employed | 23.8% | 11.2% | |
| Gearing (liabilities / total assets) | 64.5% | 4.9% | |
| Current ratio | 0.00x | 20.21x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- BDO LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“While the company has ceased to trade, the Directors do not consider it appropriate to adopt the going concern basis.”
Group structure
- ARIX BIOSCIENCE HOLDINGS LIMITED · parent
- Sorisso Pharmaceuticals Inc 0%
Significant events
- “Under the new ownership of RTW Biotech UK Limited, all investment activity has ceased, and the Company's assets were transferred or distributed.”
- “On 28 March 2025, RTW Biotech Uk Limited, the Company's parent at the period end date, transferred the ownership of the Company to RTW Biotech Opportunities Limited, a Guernsey domiciled listed company. At this point RTW Biotech UK Limited ceased to be a Person of Significant Control, and RTW Biotech Opportunities Limited became a Person of Significant Control holding directly or indirectly, 75% or more of the shares in the company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| VISTRA COSEC LIMITED | Corporate Secretary | 2024-04-12 | — | — |
| SIROTA, Stephanie | Director | 2024-02-12 | Dec 1974 | American |
| STILEMAN, Edward David | Director | 2024-02-12 | Oct 1983 | British |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| KIN COMPANY SECRETARIAL LIMITED | Corporate Secretary | 2022-02-24 | 2024-04-11 |
| ANDERSON, Joseph, Dr | Director | 2016-02-08 | 2018-09-04 |
| DAVIDSON, Thomas Charles Ramsay | Director | 2023-12-11 | 2024-02-12 |
| EVANS, Christopher Thomas, Professor | Director | 2015-09-23 | 2019-02-19 |
| KARIA, Marcus | Director | 2019-11-13 | 2021-09-30 |
| LYNE, Robert William Henry | Director | 2017-12-06 | 2023-12-31 |
| MONCREIFFE, Peregrine David Euan Malcolm | Director | 2022-02-24 | 2024-02-12 |
| PEACOCK, Jonathan | Director | 2016-02-08 | 2020-06-04 |
| RAWLINGSON, James Hedley | Director | 2016-02-08 | 2019-10-02 |
| WALTON, Martin Charles | Director | 2015-09-23 | 2016-02-08 |
| ZAHOOR, Shafia | Director | 2015-09-23 | 2017-11-17 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Rtw Biotech Opportunities Ltd | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2025-03-28 | Active |
| Rtw Biotech Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2024-02-12 | Ceased 2025-03-28 |
| Arix Bioscience Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2024-02-12 |
Filing timeline
Last 20 of 68 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-03-01 RESOLUTIONS Resolution
- 2024-02-17 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-24 | CH04 | officers | Change corporate secretary company with change date | |
| 2025-09-25 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-27 | AA | accounts | Accounts with accounts type full | |
| 2025-04-03 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-04-03 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-04-01 | RP04CS01 | confirmation-statement | Second filing of confirmation statement with made up date | |
| 2024-09-24 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-07-11 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-07-11 | AP04 | officers | Appoint corporate secretary company with name date | |
| 2024-05-22 | AA | accounts | Accounts with accounts type full | |
| 2024-05-07 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-03-01 | SH20 | capital | Legacy | |
| 2024-03-01 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-03-01 | CAP-SS | insolvency | Legacy | |
| 2024-03-01 | RESOLUTIONS | resolution | Resolution | |
| 2024-02-17 | RESOLUTIONS | resolution | Resolution | |
| 2024-02-16 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-02-16 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-02-12 | AP01 | officers | Appoint person director company with name date | |
| 2024-02-12 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-84.6%
£13,000 £2,000
-
Cash
+3,446.5%
£86,000 £3,050,000
-
Net assets
-11.7%
£44,247,000 £39,060,000
-
Employees
-55.6%
9 4
-
Operating profit
-58.6%
£10,536,000 £4,366,000
-
Profit before tax
-58.8%
£10,620,000 £4,376,000
-
Wages
+73.7%
£684,000 £1,188,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers